Bicara Therapeutics (NASDAQ:BCAX) and OptiNose (NASDAQ:OPTN) Critical Survey

Bicara Therapeutics (NASDAQ:BCAX) and OptiNose (NASDAQ:OPTN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, earnings, risk, dividends and analyst recommendations.

Insider and Institutional Ownership

85.6% of OptiNose shares are owned by institutional investors. 2.3% of OptiNose shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and price targets for Bicara Therapeutics and OptiNose, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicara Therapeutics	0	0	7	1	3.13
OptiNose	0	0	3	0	3.00

Bicara Therapeutics presently has a consensus price target of $41.20, suggesting a potential upside of 168.23%. OptiNose has a consensus price target of $16.67, suggesting a potential upside of 205.25%. Given OptiNose’s higher probable upside, analysts plainly believe OptiNose is more favorable than Bicara Therapeutics.

Profitability

This table compares Bicara Therapeutics and OptiNose’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bicara Therapeutics	N/A	N/A	N/A
OptiNose	-41.16%	N/A	-27.42%

Earnings and Valuation

This table compares Bicara Therapeutics and OptiNose”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bicara Therapeutics	N/A	N/A	N/A	N/A	N/A
OptiNose	$75.67 million	0.73	-$35.48 million	($4.20)	-1.30

Bicara Therapeutics has higher earnings, but lower revenue than OptiNose.

Summary

Bicara Therapeutics beats OptiNose on 5 of the 9 factors compared between the two stocks.

About Bicara Therapeutics

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

About OptiNose

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.